A One-Time Shot for Type 2 Diabetes? A Biotech Company Is On It
THERE’S A MAJOR downside to semaglutide, the drug originally developed for diabetes and now prescribed for weight loss under the brand names Ozempic and Wegovy: People often stop...
Read More
Fractyl Health Reports Durable Improvement in Glucose Control, Weight Loss, and Insulin Reduction in T2D Patients Using Revita® in Open Label Phase of Revitalize 1...
Read More
Fractyl Health Announces Clinical Update on Revita® Real World Registry in Germany and Launch of Revita+ Telehealth Program...
Read MorePIONEERING BREAKTHROUGH THERAPIES TO TREAT TYPE 2 DIABETES (T2D) AND OBESITY
Our vision is to develop transformative therapies that have the potential to prevent and eliminate metabolic diseases. We are a mission-driven team of innovators, singularly focused on developing therapies that are designed to target root causes of T2D and obesity and delivering those therapies to patients as broadly and rapidly as possible.
REVITA®
Revita is an outpatient procedural therapy designed to durably modify duodenal dysfunction via hydrothermal ablation in order to restore metabolic health.
Learn About RevitaSEEKING A MAJOR ADVANCE IN GLP-1 MEDICINES WITH PANCREATIC GENE THERAPY
Rejuva is a novel, locally administered, AAV gene therapy platform currently in preclinical development to improve islet function. We believe the platform represents a major advance in incretin-based therapies. PGTx is designed to potentially enable long-term remission of T2D and obesity by durably altering metabolic hormone response in the pancreatic islet cells of patients with those diseases.
Learn about Rejuva
